Visit
Post-ASH 2021 iwAL
20–21 January 2022 | Virtual Meeting
Expert-led presentations & discussions on key abstracts in ALL, AML & MDS from ASH 2021
The Post-ASH 2021 iwAL Virtual Workshop was held on 20-22 January 2022, with a packed program covering acute lymphoblastic leukemia (ALL) & myelodysplastic syndromes (MDS) on Day 1, and acute myeloid leukemia (AML) on Day 2. Both days featured a series of short presentations on selected abstracts from the 63rd ASH Annual Meeting presented by experts with interactive panel discussions after each session.
Session 1: ALL
CNS Involvement in Adult Patients with ALL Treated with a Pediatrics Protocol
Corentin Orvain Angers University Hospital, Angers, France
ALL and COVID-19 Infection: a Campus ALL Report
Sabina Chiaretti Sapienza University of Rome, Rome, Italy
Session 1 panel discussion
Session 2: Clinical trials in ALL
10-year Outcomes of UKALL 2003: Adjusting Treatment Intensity Based on MRD
Anthony Moorman Newcastle University, Newcastle upon Tyne, United Kingdom
First Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013
Nicola Gökbuget University Hospital Frankfurt, Frankfurt, Germany
Dasatinib, Prednisone, & Blinatumomab for Ph-positive or Ph-like ALL
Anjali Advani Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, United States
Phase II Study of Ponatinib & Blinatumomab for Patients with Ph-positive ALL
Nicholas Short The University of Texas MD Anderson Cancer Center, Houston, TX, United States
First Analysis of the UKALL14 Randomized Trial
Clare Rowntree Cardiff And Vale University Health Board, Cardiff, United Kingdom
First Results from the EWALL-INO Study
Philippe Rousselot University of Versailles Saint-Quentin-en-Yvelines, Versailles, France
Session 2 panel discussion
Session 3: Cellular Therapy
Treatment-Free Intervals during BiTE® Construct-mediated T-Cell Stimulation
Nora Zieger Ludwig Maximilian University of Munich, Munich, Germany
CART22-65s Co-Administered with huCART19 in Adult Patients with R/R ALL
Noelle Frey The University of Pennsylvania, Perlman School of Medicine, Philadelphia, PA, United States
Session 3 panel discussion
Session 4: Novel approaches in MDS
Molecular International Prognosis Scoring System for MDS
Elsa Bernard Memorial Sloan Kettering Cancer Center, New York, NY, United States
The Idiome & IDEAL Phase 2 Study By the GFM Group
Marie Sebert Saint-Louis Hospital, Paris, France
The Randomized Phase 3 PANTHER Trial
Mikkael Sekeres Sylvester Comprehensive Cancer Center, Miami, FL, United States
Sabatolimab in combination with HMAs in Very High/High-Risk MDS & AML
Andrew Brunner Massachusetts General Hospital, Boston, MA, United States
Session 4 panel discussion
Session 5: High-risk MDS
Molecular Responses to Ven-Aza in Treatment-Naïve High Risk MDS
Jacqueline Garcia Dana-Farber Cancer Institute, Boston, MA, United States
Venetoclax and Azacitidine for R/R MDS
Amer Zeidan Yale University School of Medicine and Yale Cancer Center, New Haven, CT, United States
Venetoclax plus ASTX727 in Treatment‐Naïve High‐Risk MDS or CMML
Sangeetha Venugopal The University of Texas MD Anderson Cancer Center, Houston, TX, United States
CPX-351 as First-Line Treatment in Higher Risk MDS: A Phase II Trial by the GFM
Pierre Peterlin Nantes University Hospital, Nantes, France
A Pilot Study of CPX-351 for Transplant Eligible, Higher Risk Patients with MDS
Rami Komrokji H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Session 5 panel discussion
Session 6: FLT-3 mutated AML
Phase 3, Open-Label, Randomized LACEWING Study
Eunice Wang Roswell Park Comprehensive Cancer Center, Buffalo, NY, United States
Presentation Coming Soon
CPX-351 versus HMA+Venetoclax As Frontline Therapy in AML
Pinkal Desai Weill Cornell Medical College, New York, NY, United States
Venetoclax with Gilteritinib Demonstrates Clearance of FLT3 Mutation
Naval Daver The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Gilteritinib Versus Salvage Chemotherapy for R/R FLT3-Mutated AML
Jianxiang Wang Institute of Hematology and Blood Diseases Hospital, Tianjin, China
IDH2-mutated R/R AML Treated with Enasidenib Vs Lower-Intensity Therapies
Courtney DiNardo The University of Texas MD Anderson Cancer Center, Houston, TX, United States
HMA Therapy and Venetoclax with FLT3 Inhibitor “Triplet” Therapy
Musa Yilmaz University of Texas MD Anderson Cancer Center, Houston, TX, United States
Session 6 panel discussion
Session 7: IDH, MLL, & Other Targeted Therapies
AGILE: Ivosidenib + Aza in Newly Diagnosed IDH1m AML
Pau Montesinos La Fe University Hospital, Valencia, Spain
A Phase 1, First-in-Human Study of SNDX-5613 (AUGMENT 101)
Eytan Stein Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Session 7 panel discussion
Session 8: Novel Frontline Therapies
Phase I/II Study of AZA-VEN plus Magrolimab in Newly Diagnosed & R/R AML
Naval Daver The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Venetoclax Added to Cladribine and Low Dose AraC in Newly Diagnosed AML
Tapan Kadia The University of Texas MD Anderson Cancer Center, Houston, TX, United States
Patients with Poor-Risk Cytogenetics Treated with Venetoclax + HMAs
Daniel Pollyea University of Colorado, Denver, CO, United States
Venetoclax with FLAG-IDA Induction & Consolidation in Newly Diagnosed AML
Curtis Lachowiez University of Texas MD Anderson Cancer Center, Houston, TX, United States
Session 8 panel discussion
Session 9: Immunotherapies
Phase 1b/2 Study of IMGN632 plus AZA-VEN for Patients with CD123+ AML
Kendra Sweet H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Combining Tagraxofusp with AZA or AZA-VEN for CD123+ AML, MDS, or BPDCN
Andrew Lane Dana-Farber Cancer Institute, Boston, MA, United States
Eprenatapopt + AZA as Maintenance for TP53m AML or MDS following HCT
Asmita Mishra H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States
Session 9 panel discussion
Meeting Supporters:
